Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

1(25.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 1(1)

N/A(1)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04552275Phase 1Recruiting

The HALT Biomarker Study

Role: collaborator

NCT02145858Completed

Prevention of Retained-Blood Outcomes With Active Clearance Technology

Role: collaborator

NCT02843022Not ApplicableCompleted

Effectiveness of a Web-based Nursing Intervention in the Reduction of Postpartum Depression and Parenting Stress.

Role: collaborator

NCT00922441Phase 2Completed

A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Role: collaborator

NCT00432536Completed

Redesigning Cardiac Surgery to Reduce Neurologic Injury

Role: collaborator

NCT01365572Phase 4Unknown

New Generation Drug Eluting Stent for In-stent Restenosis of Drug Eluting Stent( RESTENT-ISR Trial )

Role: collaborator

All 6 trials loaded